Analyst Insights

Despite Deferral Of Underground Mine, Canaccord Raises Price Target For Pan American Silver

Canaccord analyst John Kratochwil yesterday reiterated a “Hold” rating on Pan American Silver Corp (PAAS) and increased his price target to $18.75 (from $17.

William Blair Reiterates Coverage On Three Insurance Brokers

In a research report published this afternoon, William Blair analyst Adam Klauber reiterated an Outperform rating on shares of Aon plc (AON), with no price target set for the stock. Klauber commented: …

Carnival Corporation: “We Remain Neutral On The Stock”, Says William Blair

In a research note released this afternoon, William Blair analyst Sharon Zackfia reaffirmed her Market Perform rating on shares of Carnival Corporation (CCL) following the company’s second-quarter fiscal …

William Blair Initiates Coverage On Allison Transmission Holdings, Sets $36 Price Target

In a research note released this afternoon, William Blair analyst Lawrence De Maria initiated coverage on Allison Transmission Holdings, Inc. (ALSN) with an Outperform rating and …

Applied Genetic Price Target Raised To $36 At Wedbush; Sees 16% Upside

In a research note issued earlier today, Wedbush analyst David Nierengarten maintained an Outperform and boosted his price target on Applied Genetic Technologies (AGTC) to $36.00 (from $24) …

Wedbush Reiterates Outperform On Micron Technology, $37 Price Target

In a research note published today, Wedbush analyst Betsy Van Hees reiterated an Outperform rating on Micron Technology, Inc. (MU) and a price target of $37.

William Blair Reaffirms ‘Outperform’ Call On Ecolab Following Investor Meetings

In a research note released today, William Blair analyst Nate Brochmann reiterated coverage with an “Outperform” rating on Ecolab Inc. (ECL) following investor meetings with ECL’s management.

Maxim Keeps ‘Buy’ On Vertex Pharmaceuticals, Raises Price Target To $107

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on Vertex Pharmaceuticals (VRTX) and increased his price target to $107.00 (from $92.

Roth Capital Maintains Buy On Micron Technology Following 3Q14 Results

In a research report published today, Roth Capital analyst Krishna Shankar maintained a Buy rating on Micron Technology, Inc. (MU) and a price target of $37.

Roth Capital Reiterates Buy On Ligand Pharmaceutical Following Partnership With TG

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) and a price target of $92.00 following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts